NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read here
See how UMR members are aiding in the fight against the coronavirus here
A new episode of the Amazing Things Podcast is now available! Check it out here.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

COVID-19 vaccine elicits weak antibody response in people taking immunosuppressant

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors — a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions — generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis. The scientists found this was especially apparent regarding the virus’s delta variant.